Read More

Novartis Announced Plans to Petition the U.S. Supreme Court to Uphold Validity of the Gilenya Dosing Regimen Patent

Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its petition to rehear the negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for 0.5mg Gilenya. Novartis plans to file a petition seeking further review of the CAFC's decision with the US Supreme Court.